Neovascularization is required for developmental (physiological) and pathological angiogenesis. 1 The latter is found in the ischemic heart, peripheral arterial disease and tumors. Thus it is important to assist neovascularization in ischemic diseases and to block angiogenesis in cancer. 2 The vascular network of the body maintains the circulation of blood and nutrients necessary for the peripheral tissues and organs by relaxing and constricting autonomously or non-autonomously. Many of the molecules produced by endothelial cells (ECs) and vascular smooth muscle cells (VSMCs), which affect relaxation or contraction of blood vessels in both an autocrine and paracrine manner, have been identified. Among them, sphingosine 1-phosphate (S1P) released from vascular ECs stimulates S1P receptors on the ECs to induce vascular relaxation and those on the VSMCs to induce vascular contraction. 3 Vascular ECs produce nitric oxide (NO) to induce the relaxation of VSMCs. The NO-dependent cGMP-PKG signal modulated by phosphodiesterase in VSMCs is central to vascular relaxation. 4,5 On the other hand, ECs synthesize vascular contraction factors, including the metabolites of arachidonic acids. 6 Vascular contraction and relaxation are mainly regulated by the activity myosin light-chain kinase (MLC-K) controlled by the intracellular increase/decrease in Ca 2+ and Rho kinase in the signaling provoked by G protein-coupled receptors (GPCR). 7 Recently, it has been also shown that oxidative stress affects vascular cells. 8 In order to deliver nutrients and blood, vessels Development of blood vessels is coordinated by angiogenesis and stabilization of vascular endothelial cells (ECs). The vascular network is established during embryogenesis to supply oxygen and nutrients to the tissues and organs. However, after cardiac or peripheral ischemia is caused by occlusion of the vessels, new vessels must be formed to rescue the ischemic tissues. Many angiogenic growth factors and chemokines are produced in the ischemic tissue to induce angiogenic sprouting of preexisting vessels. Branched vessels must be again restabilized to form mature vessels that deliver blood to the tissues. To this end, vascular EC-cell adhesion is tightly regulated by cell-cell adhesion molecules and extracellular stimuli that activate G protein-coupled receptors and receptor tyrosine kinases exclusively expressed on vascular ECs. This review spotlights the recent studies of vascular endothelial cadherin and of sphingosine 1-phosphate signaling and angiopoietin-Tie signaling. (Circ J 2009; 73: 2183 -2191 
not only relax/contract but also loosen/tighten the cell-cell adhesions, which are constituted by endothelial-specific and common adhesion molecules. Structural characteristics of vascular ECs determine the supply of the molecules in the blood vessels across the monolayer of ECs. 9 How the molecules pass through this barrier has been extensively studied. The concentration of molecules inside or outside of the monolayer is determined by transcellular transport and paracellular permeability. 10 The transcellular transport of the molecules occurs in the fenestrated capillaries, whereas the paracellular pathway is via the continuous capillaries. The surface of the endothelial cellular that consists of glycocalyx sieves the molecules that will be subjected to the transcellular or paracellular pathway. 11 The presence of basement membrane beneath the endothelial monolayer affects the diffusion of the molecules that pass the endothelial layer. ECs are attached to the extracellular matrix (ECM) via integrin receptors to form an EC-ECM adhesion, 12 which is involved in both the transcellular and paracellular pathways. In clear contrast, the cell-cell adhesions directly control the paracellular pathway (Figure 1) .
Roles of Adhesion Molecules Expressed on Vascular ECs in Extravasation of Blood Cells
The intercellular adhesions between vascular ECs mainly constitute adherens junctions and tight junctions. Vascular ECs express endothelial-specific adhesion molecules: vascular endothelial cadherin (VE-cad), and platelet and endothelial adhesion molecule-1 (PECAM-1). [13] [14] [15] In addition to these adhesive molecules, junctional adhesion molecule (JAM), claudin-5 and nectin are involved in the formation of cell-cell contacts. [16] [17] [18] VE-cad constitutes adherens junction, whereas claudin-5, JAM and ESAM form tight junctions. Recently, VE-cad was shown to transcriptionally upregulate claudin-5 by inducing the nuclear export of βcatenin (β-ctn), which is mediated by the formation of a FoxO-1 and β-ctn complex outside of the nucleus. 19 PECAM-1 localizes in the region outside of the adherens and tight junctions 20 (Figure 2) .
The interendothelial cell-cell adhesions regulate the transendothelial migration of blood cells into the intersti- Figure 1 . Two types, continuous and fenestrated, of endothelial cells (ECs) regulate the paracellular and transcellular transport of molecules across the monolayer of the endothelium. Glycocalyx expressed on both continuous ECs and fenestrated ECs lines the luminal surface of the endothelium and limits the passage of molecules by their charge, suggesting the glycocalyx is the first stage in regulation of permeability by sieving the molecules. An electron microscopic view of the glycocalyx detected by alcian blue-lanthanium nitrate staining of rat coronary artery. Beneath the endothelium, basement membrane (BM) forms the extracellular matrix (ECM) -endothelial cell adhesion to stabilize the endothelial cells to the ECM. Furthermore, pericytes/vascular smooth muscle cells and podocytes in continuous ECs and fenestrated glomerular ECs support the ECs by respectively forming cell-cell contacts and by secreting angiopoietin-1.
Figure 2.
Schema of how leukocytes extravasate across the endothelium and the intercellular adhesion molecules of the endothelium. Local inflammation requires an accumulation of leukocytes across the endothelium through several steps: attachment of leukocytes to the endothelium, rolling of leukocytes on the endothelium, firm attachment of leukocytes to the endothelium via integrin, and transmigration via cell-cell adhesion molecules. Cell-cell junction molecules not only participate in the extravasation of blood cells but also directly regulate loosening and tightening of the cellcell adhesion. Assembly of cortical actin augments the accumulation of VE-cadherin (VEcad), but not PECAM-1, at the cell-cell contact by being linked to VE-cad through β-ctn and α-ctn. JAM, junctional adhesion molecule; PECAM-1, platelet and endothelial cell adhesion molecule-1, p120ctn, p120 catenin; β-ctn, β-catenin; α-ctn, α-catenin. tial cells, as well as permeability. There are several steps observed in leukocyte recruitment to ECs: initial attachment and rolling of leukocytes through their interaction with integrin (leukocytes) and p-and e-selectins (ECs), then firm attachment and subsequent recruitment of leukocytes to the cell-cell junction mediated by the interaction between integrins on the leukocytes and ICAM-1/VCAM-1 on the ECs and transmigration mediated by several molecules expressed on the interendothelial junction. 21 This interaction has become a target for reducing inflammation. 22 The homophilic association of PECAM-1 contributes to transendothelial migration after the initial attachment of the leukocytes to ECs. 23 The engagement of integrins with ICAM-1 results in phosphorylation of VE-cad, thereby weakening the VE-cad-mediated cell-cell junctions. 24 Thus, VE-cad works as the gate keeper against leukocytes, which induce inflammation (Figure 2) .
In this review, I focus on vascular integrity controlled by the VE-cad-mediated cell-cell adhesion, angiopoietin-1 (Ang1)-Tie2 signaling and the S1P-mediated signal as representative cell adhesion molecules, tyrosine kinase receptor-mediated signals and GPCR-mediated signals, respectively. The atrial natriuretic peptide family of molecules is essential for vascular integrity by activating their receptors and exerting guanylate cyclase activity. The beneficial effects of natriuretic peptides on the vasculature have been reviewed. 25, 26 
Control of Vascular Integrity Permeability Regulating Factors
Increased vascular permeability is found in inflammation, hypoxia and thrombosis. Under these conditions, vascular permeability is either enhanced or reduced by extracellular stimuli that activate cell surface receptors, tyrosine kinases and GPCRs. Vascular endothelial growth factor (VEGF) is a vascular permeability increasing factor, 27 whereas Ang1 activates Tie2 receptor tyrosine kinase and counteracts the VEGF-VEGFR-2 signal to maintain vascular integrity. 28, 29 Several permeability-increasing factors are induced through GPCR activation. Thrombin is concentrated in clots and released into the blood to activate PAR-1, which is activated when its amino-terminus is cleaved upon throm-bin stimulation, and it then signals to Gq and G12/13 proteins to increase permeability. 30 Gq and G12/13 activation leads to increased intracellular Ca 2+ , which enhances activation of calmodulin kinase (CaM-K)/MLC-K, leading to activation of Rho-Rho kinase to reduce MLC phosphatase. Both signals result in actin-myosin-dependent contraction of vascular ECs. 31 Bradykinin produced from kininogen in the blood acts on the Gq/i protein-coupled B1 and B2 receptors expressed on ECs to increase permeability. 32 In contrast to thrombin, bradykinin induces vascular permeability independently of MLC-K and Rho kinase. 33 Histamine released from mast cells also transiently increases permeability, compared with thrombin, by activating H1 receptors expressed on ECs. 34 Platelet-activating factor augments vascular permeability independently of the actin-myosin contraction, similar to bradykinin 33 (Figure 3 ).
VE-Cad Regulates Barrier Function in ECs
VE-cad and N-cadherin belonging to the classical cadherin family that are expressed on the endothelium and undergo Ca 2+ -dependent homophilic trans-and cis-interactions. VEcad accumulates at the interendothelial cell-cell junctions, whereas N-cadherin is mostly located between ECs and smooth muscle cells. 35, 36 In contrast, there is a report of localization of N-cadherin at the interendothelial junctions. 37 Similar to other classical cadherins, VE-cad is a single-membrane-spanning molecule that contains 5 extracellular cadherin domains, a transmembrane domain and a cytoplasmic domain that binds p120 catenin (p120ctn) and β-ctn at the juxtamembrane domain and the carboxy terminal domain, respectively. 38 The expression of VE-cad is regulated by many steps: shedding, endocytosis, synthesis, transport and stabilization at the cell-cell contacts (Figure 4) . The extracellular domain of VE-cad is detected in the culture medium from apoptotic ECs, indicating shedding of VE-cad. 39 Recently, the metalloprotease-disintegrin, ADAM9, was reported to potentially cleave VE-cad. 40 VEGF induces endocytosis of VE-cad through the phosphorylation of VE-cad at Ser 665. Activation of Rac by Vav2 in VEGF-stimulated cells leads to PAK-dependent phosphorylation of Ser at 665, resulting in endocytosis of VE-cad in a manner dependent on β-arrestin2. 41 Src tyrosine Circulation Journal Vol. 73, December 2009 kinase is involved in the Vav2-Rac-PAK signal-mediated phosphorylation of VE-cad. Although phosphorylation of the cytoplasmic domain of VE-cad is accompanied by an increase in vascular permeability in vitro and in vivo, 42, 43 it has not been explored whether tyrosine-phosphorylated VE-cad is prone to endocytosis. Src is also involved in tyrosine phosphorylation of VE-cad. 44 VE-cad associates with VEGFR-2 (Flk-1) and reduces the internalization of VEGFR-2. 45 The significance of the association of VE-cad with VEGFR-2 is confirmed by mice lacking the entire VE-cad and those lacking its cytoplasmic domain, 46 although the precise mechanism of VEGF-mediated internalization of VE-cad has yet to be clarified.
The VE-cad promoter has been isolated and is used as an endothelial-specific promoter. 47 There are 2 conserved Ets binding sites in the 5' region (within −200 bp) of the transcription initiation site of the VE-cad gene (CDH5). Chromatin immunoprecipitation assay confirms that Erg is capable of binding these 2 sites. Perturbation of Erg using antisense oligonucleotides reduces the expression of VEcad in HUVECs, indicating the involvement of Erg in the transcriptional regulation of VE-cad. 48 There are 6 potential and putative hypoxia response elements, suggesting the regulation of VE-cad expression by hypoxia-inducible factors (HIF-1α and HIF-2α). 49 Although CDH5 is not responsive to hypoxia, HIF-2α, but not HIF-1α, activates the promoter of VE-cad. Serum response factor (SRF) is also reported to be required for the expression of VE-cad, as confirmed by the depletion of SRF in the vascular ECs of mice. 50 SRF binds to CArG box found in the regulatory regions of CDH5.
The cytoplasmic domain of VE-cad is important for the trafficking and stabilization of VE-cad because it provides the binding sites for p120ctn and β-ctn. The amount of p120ctn determines a set point mechanism that regulates cadherin expression levels by controlling the internalization and degradation of VE-cad. 51 Reduction of p120ctn by siRNA results in decreased expression of endogenous VE-cad. Forced expression of p120ctn reduces the clathrinmediated endocytosis of VE-cad. 52 The essential role of the association between p120ctn and VE-cad is supported by evidence that overexpression of the juxtamembrane domain of VE-cad reduces VE-cad expression and barrier function. 53 Furthermore, p120ctn regulates the transendothelial migration of leukocytes by altering the tyrosine phosphorylation of VE-cad. 54 Conversely, phosphorylation of VE-cad at Tyr658 and Tyr731 inhibits binding of p120ctn to VE-cad. 44 Phosphorylation of the 2 tyrosines correlates with a reduction in the barrier function of ECs. Another study reports that Golgi-associated cPLA2α regulates the transport of VE-cad, as well as claudin-5, from the Golgi apparatus to the cell-cell junction. 55 The β-ctn binding to E-cadherin is well known as linking link E-cadherin to actin via α-catenin ( α-ctn) to stabilize E-cadherin-mediated cell-cell adhesion. 56 Thus, similar to E-cadherin, VE-cad is thought to be linked to actin fibers to maintain the integrity of endothelial adhesions. Depletion of β-ctn in the ECs of mice results in defective vascular patterning, suggesting the critical role of β-ctn in interendothelial adhesions. 57 Therefore, stabilization of VE-cad depends on the link between VE-cad and actin. However, this classical model is challenged by the Nelson 58 and Weis groups. 59 They claim that α-ctn does not connect actin fibers to E-cadherin and propose a dynamic model instead of the classical static model. In addition, phosphorylation of β-ctn as well as VE-cad affects the binding of β-ctn to VE-cad. There are several phosphatases that dephosphorylate the molecules participating in the regulation of cell-cell adhe- sions. Thrombin induces phosphorylation of SHP2 and its dissociation of VE-cad, resulting in the phosphorylation of β-ctn and a reduction of the amount of β-ctn that binds to VE-cad. 60 The requirement of vascular endothelial protein tyrosine phosphatase (VE-PTP) has been demonstrated. 61 Downregulation of VE-PTP enhances EC permeability and inhibits VE-cad adhesion. The essential substrate of VE-PTP in VE-cad-dependent cell-cell adhesions is plakoglobin, not β-ctn. DEP-1/CD148 is reported to be required for VEcad-dependent inhibition of VEGFR-2 activation. 62 The cellular actin cytoskeleton that determines cell shape is regulated by the Rho-family GTPases (Rho, Rac and Cdc42). Indeed, Rho-family GTPases are involved in cadherin-mediated cell-cell adhesion by controlling the actin-based cytoskeleton. 63 Besides the Rho-family GTPases, Rap1, a small GTPase, is well known for stabilizing the VE-cad-mediated cell-cell adhesion. 64, 65 
Stabilization of VE-Cad at the Cell-Cell Contact by Rap1-Mediated Signal
We have previously shown that MAGI-1 binding to β-ctn recruits PDZ-GEF1, a guanine nucleotide exchange factor (GEF) for Rap1, thereby activating Rap1 at the interendothelial junctions upon engagement of VE-cad. 66 My and others further demonstrate that the cAMP-Epac (another GEF for Rap1) -Rap1 signal stabilizes the VE-cad-mediated cell-cell adhesion. 67, 68 Although cAMP-increasing stimuli are known to stabilize the cell-cell adhesion via protein kinase A (PKA), Epac instead of PKA is critical for cAMP-induced stabilization. Accumulation of VE-cad at the cell-cell contacts is increased by an Epac-specific activator, 8-pCPT-2'-O-Me-cAMP (known as 007), as well as forskolin in vitro and in vivo. 67, 69 007 not only reduces EC permeability, but also inhibits transendothelial migration of leukocytes. 70 Although the downstream effectors of Rap1 in the stabilization of VE-cad are not fully understood, several potential signaling pathways have been suggested. Cerebral cavernous malformation (CCM) is associated with defective endothelial junctions. There are 3 genes related to CCM: CCM1, CCM2 and CCM3. 71,72 CCM1/KRIT1 (K-Rev1 interaction trapped gene 1), a Rap1-binding protein, is reported to be involved in Epac1/Rap1-regulated permeability of EC-cell junctions. 73 KRIT1 localizes at the cell-cell contacts and associates β-ctn, thereby being indirectly connected to VEcad. CCM2 functions as a scaffold protein and forms complexes with CCM1 and CCM3. 74 CCM1 might connect the heart-of-glass (Heg)-mediated signal to CCM2 to maintain vascular structure, as well as VE-cad-β-ctn. 75 Target disrup- Circulation Journal Vol. 73, December 2009 tion of Ccm2 in mice results in failure of lumen formation and embryonic lethality. Whitehead et al showed activation of RhoA in CCM2-depleted cells and alteration of cell-cell junctional structure because of the activation of RhoA. 74 Therefore, the Rap1-CCMs signal is proposed to regulate the cell-cell adhesion through modification of the RhoA signaling that controls the actin cytoskeleton.
Rap1 has been demonstrated to regulate actin cytoskeleton via signaling to Rho-family GTPases. Rap1 is capable of activating Rac and determining the localization of GFEs, Vav2 and Tiam1 for the Rho-family GTPases. 76 Cell-cell contactdependent engagement of nectin induces the activation of Rap1 and subsequent activation of Rac and Cdc42 via Vav2 and FRG, respectively. 15 The role of affadin, which can bind to Rap1, nectin, and zonula occludens-1 (ZO-1), has not been clearly investigated in the Rap1-mediated signal, although its role in the EC-ECM has been characterized. 77 Rho-family GTPases are regulated by other molecules localized at the cell-cell contacts. p120ctn and RhoA mutually inhibit their functions by binding each other. 78 p120ctn balances the activity of Rho and Rac by binding to p190RhoGAP at the cell-cell contacts when p190RhoGAP is recruited to the cell-cell contacts upon growth factor stimulation. 79 In the light of cortical actin-dependent stabilization of VE-cad, how Rap1 regulates VE-cad stabilization at the cell-cell contacts has been investigated. Although the static linkage of cadherin and actin is challenged by the Nelson 58 and Weis groups, 59 the importance of the link between cadherin and actin cytoskeleton has not been contradicted. The importance of the link between VE-cad and actin can be claimed by comparing VE-cad with PECAM-1, which is not linked to actin. Thus, my group used a fluorescence recovery after photobleaching (FRAP) experiment using VE-cad or PECAM-1 tagged with green fluorescence protein (GFP) (VE-cad-GFP and PECAM-1-GFP, respectively) to monitor the dynamics at the junctions. We found that for-skolin induces cortical actin bundling parallel to the cellcell contacts. The mobile fraction of VE-cad was decreased upon forskolin stimulation, while that of PECAM-1 was unchanged, suggesting a significant link between actin and cell adhesion molecules for the stabilization of adhesion molecules at the cell-cell contacts when the formation of cortical actin bundling is augmented (unpublished data). The precise molecular mechanism of how Rap1 regulates the stabilization of VE-cad at the cell-cell contact needs to be clarified (Figure 5 ).
Ang1/Tie2-Mediated Integrity of Vascular ECs
Ang1 activates Tie2 receptor tyrosine kinase and counteracts the VEGF-VEGFR-2 signal to maintain vascular integrity. 28, 29 Another angiopoietin, Ang2, is thought to compete with Ang1 and induce angiogenesis. 80 Ang1 strengthens the PECAM-1-and VE-cad-mediated intercellular junctions by inducing the dephosphorylation of PECAM-1 and VEcad and by inhibiting TNF-α-induced transmigration of leukocytes. 81 We and others have demonstrated that Ang1 localizes Tie2 to the intercellular junctions by bridging Tie2. 82, 83 Trans-associated Tie2 preferentially activates AKT and reduces permeability. VE-PTP is also recruited to the cell-cell junctions when stimulated by Ang1, suggesting a potential role in reducing the permeability mediated by enhanced accumulation of VE-cad. Antibody against VE-PTP can mimic depletion of VE-PTP and induces activation of Tie2. Thus, the association of VE-PTP with Tie2 appears to be very important for the regulation of endothelial stabilization and proliferation. 84 We further extended our studies of the function of trans-associated Tie2 at the cellcell contacts. Analysis of gene expression by cDNA array enabled identification of the responsible molecules that promote vascular quiescence, 1 of them being Krüppel-like factor 2 (KLF2). 82 KLF2 is a zinc finger transcription factor that belongs to the KLF family and is expressed in vascular . Angiopoietin-1 (Ang1) secreted from pericytes induces the trans-association of Tie2 at the cell-cell contact and subsequently activates the Akt-MEF2-KLF2 signal. KLF2 promotes the expression of endothelial nitric oxide synthase and reduces the expression of VCAM-1. Therefore, the Ang1-Tie2 signal is anti-inflammation and pro-quiescence (Upper). Sphingosine 1-phosphate (S1P) is produced from sphingosine (Sph) in the plasma membrane by sphingosine kinase (Sph-K) in the cytoplasm. Thus, to activate sphingosine 1-phosphate receptor 1 (S1P1) that governs vascular stability, S1P is released outside the cell from the cytoplasm. Spinster2 (Spns2) functions as a S1P transporter. Thus, Spns2 is likely to participate in S1P-mediated signaling in a paracrine or autocrine manner to control vascular integrity (Lower).
ECs. 85 The importance of KLF2 for the stability of blood vessels is confirmed by deletion of KLF2. 86 One can speculate that KLF2 is a vascular protective transcription factor because it upregulates endothelial NO synthase (eNOS), natriuretic peptides and downregulates VCAM-1, E-selectin, VEGFR-2, and endothelin-1.
My group delineated the signaling downstream of activated Tie2 at the cell-cell contacts. 87 Upregulation of KLF2 is dependent on MEF2, but not ERK5, which is regulated by the phosphatidylinositol 3-kinase (PI3K)-AKT signal. Attachment of monocytes to cultured ECs stimulated with VEGF was impeded by Ang1. This inhibition was reversed by the depletion of KLF2, indicating that the inhibitory effect of Ang1 on inflammatory cell adhesion to ECs is regulated by KLF2. Therefore, we conclude that Ang1-dependent stability of ECs depends on KLF2 (Figure 6) . S1P Regulates Integrity of ECs S1P is thought to be released from activated platelets and erythrocytes. 88, 89 Its receptors, S1P1-S1P5, are GPCR and expressed in various tissues, including vascular ECs and VSMCs. 90 S1P1 is coupled to Gi and induces PI3K-dependent eNOS and Rac activation, whereas S1P2 and S1P3 are coupled to Gi, Gq, and G12/13. 91 Activation of Gq and that of G12/13 results in phosphorylation of MLC and subsequent actin-myosin-dependent contraction via the phospholipase C-β (PLCβ)-Ca 2+ /CaM kinase signal and RhoA-Rho kinase signal, respectively. 91 Vascular integrity controlled by S1P is dependent on Gi-Rac-PAK signaling that induces re-arrangement of the actin cytoskeleton. 92 S1P-mediated enhancement of the ECs barrier function is explained by the phosphorylation of cortactin and its binding to MLC-K. 93 ZO-1 is essential for the S1P-regulated barrier integrity of ECs, as evidenced by the fact that depletion of ZO-1 leads to loss of the S1Penhanced barrier function. 94 The association of VE-cad with β-ctn-focal adhesion kinase upon S1P stimulation regulates the cortical actin rearrangement that stabilizes the cell-cell junction. 95 Plasma S1P-less mice in which sphingosine kinases (I and II) are knocked out show vascular leakage, suggesting the mechanism of S1P1-regulated vascular integrity of ECs in vivo. 96 Thus, maintenance of vascular EC integrity is regulated by S1P without activation of platelets.
From which cells is S1P released? S1P is synthesized from sphingosine localized in the plasma membrane by sphingosine kinase I and II in the cytoplasm. 97 Therefore, S1P produced in the cells must be released from inside to outside of the cells via transporters that activate S1P receptors. There are 3 ABC transporters, ABCC1, ABCA1, and ABCA7, which might function as the S1P transporter. [98] [99] [100] It is still controversial whether these transporters function in vivo to maintain vascular integrity. My group recently identified a novel S1P transporter, Spinster2 (Spns2), by screening zebrafish mutants that show cardia bifida. 101 The Spns family consists of Spns1, Spns2 and Spns3. The mutants showing cardia bifida harbored a R153S mutation of Spns2, indicating that it was the gene responsible. Stainier's group previously reported that deletion of S1P2 causes cardia bifida in both zebrafish 102 and another mutant fish. By analyzing the latter, they also demonstrated that the gene responsible for the phenotype was a mutation of Spns2. 103 We assumed that Spns2 might function as a S1P transporter because it appears to span the membrane 12 times according to its amino acid sequence. Therefore, we investigated the export activity of S1P using cells expressing wild-type Spns2 and mutant Spns2 (R153S) and found that Spns2 functioned as a transporter of S1P. Collectively, S1P released from vascular ECs via Spns2 might activates S1P1 expressed on vascular ECs to maintain vascular integrity (Figure 6 ).
Conclusion
Vascular EC integrity is important for protecting the vasculature from thrombosis, atherosclerosis and abnormal angiogenesis. Because the ideal vasculature is organized during embryonic development, established blood vessels need to be maintained to keep blood flowing smoothly around the body. In this review, I have focused on the molecules that are central to the stability of vascular ECs. Other vascular stabilization factors besides Ang1 and S1P will be identified to extend our knowledge of vascular integrity. Destabilization of cell-cell contacts is required for preexisting vessels to promote the angiogenesis that should be re-stabilized once ischemia is improved. Therefore, it is necessary to understand the stabilization and destabilization cycle in the vasculature under both pathological and physiological conditions. We, as cardiologists, are expected to develop new therapeutic strategies to rescue and reverse the damaged heart by regenerative medicine. We need to think about the regeneration of healthy vasculature, as well as the myocardium, to regenerate the heart. Thus, it is important for us to instigate understanding of how we can control both regeneration and maintenance of preexisting tissues.
